Niels W C J van de Donk Selected Research

Bortezomib (Velcade)

12/2023	Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
1/2023	Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
10/2021	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
11/2016	Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
6/2015	Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
10/2013	Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.
8/2013	New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
6/2011	Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
4/2006	Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Niels W C J van de Donk Research Topics

Disease

112	Multiple Myeloma 04/2024 - 11/2003
31	Neoplasms (Cancer) 04/2024 - 11/2003
7	Infections 03/2024 - 01/2020
7	Lymphoma (Lymphomas) 01/2022 - 11/2003
6	Disease Progression 07/2023 - 03/2016
4	Residual Neoplasm 01/2023 - 01/2021
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2021 - 01/2018
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 07/2023 - 01/2022
3	Cytokine Release Syndrome 01/2023 - 11/2020
3	Body Weight (Weight, Body) 12/2022 - 09/2015
3	Hematologic Neoplasms (Hematological Malignancy) 07/2021 - 03/2016
3	Monoclonal Gammopathy of Undetermined Significance 01/2021 - 06/2014
3	Chromosome Aberrations (Chromosome Abnormalities) 12/2020 - 09/2012
2	Neutropenia 11/2023 - 10/2021
2	COVID-19 01/2023 - 01/2020
2	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021 - 10/2010
2	Smoldering Multiple Myeloma 01/2021 - 01/2020
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018 - 01/2016
2	Anemia 10/2015 - 09/2012
1	Fever (Fevers) 11/2023
1	Sudden Death 09/2023
1	Polyneuropathies (Polyneuropathy) 09/2023
1	Ageusia (Hypogeusia) 08/2023
1	Uveal melanoma 01/2023
1	Sepsis (Septicemia) 11/2022
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022
1	Lymphopenia (Lymphocytopenia) 10/2021
1	Septic Shock (Toxic Shock Syndrome) 10/2021
1	Hypertension (High Blood Pressure) 10/2021
1	Fibrosis (Cirrhosis) 04/2021

Drug/Important Bio-Agent (IBA)

42	daratumumabIBA 12/2023 - 02/2015
18	Monoclonal AntibodiesIBA 12/2023 - 10/2014
16	Lenalidomide (CC 5013)FDA Link 12/2023 - 06/2011
15	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 04/2024 - 01/2020
14	B-Cell Maturation AntigenIBA 04/2024 - 01/2020
13	AntibodiesIBA 11/2023 - 03/2016
12	Bispecific AntibodiesIBA 04/2024 - 11/2020
12	Chimeric Antigen ReceptorsIBA 01/2024 - 01/2016
10	Dexamethasone (Maxidex)FDA LinkGeneric 12/2023 - 11/2003
9	Bortezomib (Velcade)FDA Link 12/2023 - 04/2006
9	AntigensIBA 11/2023 - 01/2017
7	CytokinesIBA 04/2024 - 01/2016
7	Proteasome InhibitorsIBA 11/2022 - 08/2013
6	Proteins (Proteins, Gene)FDA Link 01/2024 - 06/2014
6	Thalidomide (Thalomid)FDA Link 09/2023 - 04/2006
6	pomalidomideIBA 11/2022 - 01/2018
5	ixazomibIBA 09/2023 - 01/2018
4	Immunoconjugates (Immunoconjugate)IBA 01/2023 - 01/2020
4	Immunomodulating AgentsIBA 11/2022 - 08/2013
3	EpitopesIBA 07/2023 - 03/2016
3	Prednisone (Sone)FDA LinkGeneric 09/2018 - 03/2016
3	Lovastatin (Mevacor)FDA LinkGeneric 01/2006 - 11/2003
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2024 - 01/2021
2	Surface Antigens (Surface Antigen)IBA 01/2024 - 01/2017
2	VaccinesIBA 12/2023 - 01/2023
2	Immunoglobulin G (IgG)IBA 11/2023 - 06/2014
2	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 03/2016
2	elotuzumabIBA 11/2020 - 01/2018
2	SurvivinIBA 01/2020 - 10/2013
2	isatuximabIBA 01/2019 - 01/2018
2	felzartamabIBA 01/2019 - 01/2018
2	Immune Checkpoint InhibitorsIBA 01/2019 - 01/2018
2	ADP-ribosyl Cyclase 1IBA 01/2019 - 01/2017
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2018 - 11/2016
2	Antigen Receptors (Antigen Receptor)IBA 01/2017 - 01/2016
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 04/2006 - 01/2006
1	Fc Receptors (Fc Receptor)IBA 01/2024
1	Intravenous Immunoglobulins (IVIG)FDA Link 12/2023
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2023
1	Keratins (Keratin)IBA 08/2023
1	molnupiravirIBA 01/2023
1	remdesivirIBA 01/2023
1	crisamicin AIBA 01/2023
1	Peptide FragmentsIBA 01/2023
1	Antiviral Agents (Antivirals)IBA 01/2023
1	Dihydrotachysterol (AT 10)IBA 01/2023
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023
1	CreatinineIBA 01/2023
1	nirmatrelvir and ritonavir drug combinationIBA 01/2023
1	RNA (Ribonucleic Acid)IBA 12/2022
1	tetraethylpyrazine (TEP)IBA 12/2022
1	iberdomideIBA 11/2022
1	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 01/2022
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 12/2021
1	SolutionsIBA 11/2021
1	Peptides (Polypeptides)IBA 11/2021
1	Granzymes (Granzyme)IBA 10/2021
1	durvalumabIBA 05/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021
1	GlycolipidsIBA 01/2021
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2021

Therapy/Procedure

32	Therapeutics 03/2024 - 06/2015
10	Immunotherapy 01/2024 - 10/2013
9	Stem Cell Transplantation 01/2022 - 04/2006
3	Transplantation 12/2023 - 01/2017
3	Drug Therapy (Chemotherapy) 01/2017 - 04/2006
2	Radiotherapy 11/2018 - 10/2010
1	Aftercare (After-Treatment) 10/2023
1	Subcutaneous Injections 11/2022